Stanford inventors have developed a near infrared (NIR) tumor imaging platform that couples a novel rare earth cancer targeting agent and a handheld NIR-IIb fluorescence imager to enable tumor resection down to the few-cell level.
Researchers at Stanford have developed a probe, NIRDye812, which improves contrast between healthy and diseased tissues for fluorescence-guided cancer surgery applications.